HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Influence of intravenous immunoglobulin therapy on autoantibody titres to BP Ag1 and BP Ag2 in patients with bullous pemphigoid.

AbstractBACKGROUND:
Bullous pemphigoid (BP) is a subepidermal autoimmune blistering disease, which is characterized by blisters on the skin. Autoantibodies to components of the basement membrane zone are usually observed in the sera of patients with BP. Autoantibodies to the bullous pemphigoid antigens (BP Ag1, 230-kDa desmoplakin protein, and BP Ag2, 180-kDa hemidesmosomal protein) are present in the sera of BP patients.
OBJECTIVE:
The objective of this study was to report the influence of intravenous immunoglobulin (IVIg) therapy on autoantibody titres to BP Ag1 and BP Ag2.
METHODS:
In this prospective study, we measured autoantibody titres to both BP Ag1 and BP Ag2, in 10 patients with severe BP, over a period of 18 consecutive months on each patient, using an immunoblot assay.
RESULTS:
Prior to the initiation of IVIg therapy, the sera of nine patients demonstrated the presence of high autoantibody titres to both BP Ag1 and BP Ag2. One patient had autoantibodies to BP Ag1 only. A statistically significant decline in the autoantibody titres to both BP Ag1 and BP Ag2 was observed after 3 months of receiving the first cycle of IVIg therapy. This gradual decline in autoantibody titres continued until patients were observed to have non-detectable titres to BP Ag1 after 11 months and to BP Ag2 after 10 months of receiving IVIg therapy. Once patients achieved non-detectable titres, these patients were considered to be in a serological remission. This serological remission was sustained for an additional 7 months of observation.
CONCLUSION:
Autoantibody titres to BP Ag1 and BP Ag2 can be used to monitor the serological response to treatment in patients with BP. Patients with severe BP who are treated with IVIg therapy, as described in our protocol, achieve a long-term serological remission.
AuthorsN Sami, S Ali, K C Bhol, A R Ahmed
JournalJournal of the European Academy of Dermatology and Venereology : JEADV (J Eur Acad Dermatol Venereol) Vol. 17 Issue 6 Pg. 641-5 (Nov 2003) ISSN: 0926-9959 [Print] England
PMID14761129 (Publication Type: Comparative Study, Journal Article)
Chemical References
  • Autoantibodies
  • Autoantigens
  • Carrier Proteins
  • Cytoskeletal Proteins
  • DST protein, human
  • Dystonin
  • Immunoglobulins, Intravenous
  • Nerve Tissue Proteins
  • Non-Fibrillar Collagens
  • Collagen
Topics
  • Aged
  • Aged, 80 and over
  • Analysis of Variance
  • Autoantibodies (drug effects, immunology)
  • Autoantigens (analysis, immunology)
  • Carrier Proteins
  • Case-Control Studies
  • Collagen (analysis, immunology)
  • Cytoskeletal Proteins
  • Dose-Response Relationship, Drug
  • Drug Administration Schedule
  • Dystonin
  • Enzyme-Linked Immunosorbent Assay
  • Female
  • Follow-Up Studies
  • Humans
  • Immunization, Passive (methods)
  • Immunoblotting
  • Immunoglobulins, Intravenous (administration & dosage)
  • Male
  • Nerve Tissue Proteins
  • Non-Fibrillar Collagens
  • Pemphigoid, Bullous (immunology, therapy)
  • Prospective Studies
  • Reference Values
  • Risk Assessment
  • Severity of Illness Index
  • Treatment Outcome
  • Collagen Type XVII

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: